HC Wainwright Has Positive Forecast for RNAC FY2026 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – HC Wainwright upped their FY2026 earnings estimates for Cartesian Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($2.28) per share for the year, up from their prior forecast of ($2.91). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q4 2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($1.08) EPS, Q2 2027 earnings at ($0.94) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($3.61) EPS.

Several other equities research analysts have also weighed in on RNAC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cartesian Therapeutics in a research note on Wednesday, September 9th. Zacks Research upgraded Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Cartesian Therapeutics in a research note on Tuesday, August 18th. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday, September 29th. Finally, Wall Street Zen upgraded Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Cartesian Therapeutics Stock Performance

Shares of RNAC opened at $7.02 on Tuesday. The company has a 50-day moving average price of $7.35 and a two-hundred day moving average price of $7.64. Cartesian Therapeutics has a 12 month low of $5.60 and a 12 month high of $11.00.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of RNAC. Privium Fund Management B.V. grew its position in Cartesian Therapeutics by 2.2% during the 3rd quarter. Privium Fund Management B.V. now owns 155,000 shares of the company’s stock worth $1,118,000 after acquiring an additional 3,325 shares during the last quarter. Squarepoint Ops LLC raised its position in Cartesian Therapeutics by 0.7% in the 2nd quarter. Squarepoint Ops LLC now owns 2,254,619 shares of the company’s stock valued at $23,493,000 after purchasing an additional 16,133 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Cartesian Therapeutics in the 2nd quarter valued at $332,000. Renaissance Technologies LLC boosted its stake in Cartesian Therapeutics by 63.7% in the first quarter. Renaissance Technologies LLC now owns 67,300 shares of the company’s stock worth $414,000 after purchasing an additional 26,200 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in Cartesian Therapeutics in the first quarter worth $78,000. 86.95% of the stock is owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).